Company · DSE:ORIONINFU · Pharmaceuticals & healthcare · Analysis · 31 Oct 2026
Orion Infusion: FY2025 sales fell 20% to BDT 665m and 9M FY2026 sales fell a further 3.5%, while the shares trade at 131x trailing earnings
Bangladesh's largest dedicated IV-fluid maker has not grown in ten years: revenue was BDT 730m in FY2016 and BDT 665m in FY2025. ROE has stayed at 11-16%, a BDT 306m bank line costs 12.9%, and capacity use fell to 75%. A BDT 205m line expansion, to be funded internally, is due to finish in December 2026.
Orion Infusion Limited (OIL) makes intravenous (IV) fluids and other injectable "parenteral" products at a single plant and sells them to hospitals, clinics and pharmacies across Bangladesh. It is a member of the Orion Group, listed on the Dhaka Stock Exchange in 1994, and has…
Company · DSE:ORIONPHARM · Pharmaceuticals & healthcare · Analysis · 29 Oct 2026
Orion Pharma: power revenue fell 88% after the plant contracts expired, leaving a BDT 25.6bn debt load on a pharma business earning BDT 251m
FY2025 consolidated revenue fell 61.6% to BDT 4.08bn and the group lost BDT 415m. The auditor qualified its opinion over a restated UCB loan and a BDT 651m claim on an individual; the shares have been in DSE's Z category since 5-Feb-2025 over an unpaid dividend.
Orion Pharma Limited is a listed generic-medicine maker that also owns two power plants and holds shares in other Orion group companies. It owns 95% of Orion Power Meghnaghat Limited and 67% of Dutch Bangla Power & Associates Limited, each a 100 MW heavy-fuel-oil quick…
Company · DSE:NAVANAPHAR · Pharmaceuticals & healthcare · Analysis · 29 Oct 2026
Navana Pharmaceuticals: sales up 28% and factories at 98% of capacity, but interest takes half of operating profit
FY2025 net sales rose 28.2% to BDT 8.84bn and operating profit 45.4%, yet finance expenses of BDT 750m left a 5.5% net margin. Borrowings fell from BDT 5.27bn to BDT 3.78bn by March 2026; FY2026 EPS was BDT 5.93.
Navana Pharmaceuticals PLC makes and sells generic medicines for people and animals in Bangladesh, and exports a small part of its output. Its fiscal year runs from 1 July to 30 June; FY2025 is the year to 30-Jun-2025. The company was incorporated in 1986, merged…
Company · DSE:IBNSINA · Pharmaceuticals & healthcare · Analysis · 29 Oct 2026
IBN SINA Pharmaceutical: 9M FY2026 sales up 18% as the Mawna plant lifts capital work-in-progress to BDT 4.1bn, funded mostly with debt
Sales rose every year for ten years, at 4.5-24.6% a year, with steady 40-42% gross margins; selling and distribution takes 30% of revenue, so ROE fell from 24-25% to 17% in FY2025. The FY2026 cash dividend is 77%, the highest yet.
The IBN SINA Pharmaceutical Industry PLC (IPI) makes and sells allopathic ("pharma") medicines and, through its subsidiary The IBN SINA Natural Medicine Ltd., Unani, Ayurvedic and herbal products. Its fiscal year ends on 30 June: the audited FY2025 statements cover 1-Jul-2024 to 30-Jun-2025. Group revenue…
Company · DSE:ASIATICLAB · Pharmaceuticals & healthcare · Analysis · 29 Oct 2026
Asiatic Laboratories: sales doubled in 9M FY2026 after a debt-funded plant upgrade, while 68% of the IPO money sat unused at June 2025
Nine-month revenue rose 99% to BDT 2,288m and EPS to BDT 3.97, but the company borrowed BDT 1.03bn in FY2025, BSEC extended the sponsors' lock-in over IPO-fund use and a planned 32-storey building, and the share price, BDT 108.0 on 29-Oct-2026, is 3.9 times its October 2024 low of BDT 27.8.
Asiatic Laboratories Limited (ALL) is a small Bangladeshi maker of branded generic medicines: tablets, capsules, oral liquids, powder for suspension, ophthalmic drops and injectables, made at one plant in the Tongi industrial area of Gazipur. It was incorporated in 1970, began commercial operation in 1998,…